KRRO vs KURA

Korro Bio, Inc. vs Kura Oncology, Inc. — Valuation Comparison 2026

KRRO

Pharmaceutical Preparations
Korro Bio, Inc.
Quality
5.1
out of 10
Value Trap
28
LOW
Price
$13.41
Last close
Models
9/13
Active
VS

KURA

Pharmaceutical Preparations
Kura Oncology, Inc.
Quality
5.6
out of 10
Value Trap
12
SAFE
Price
$10.20
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType KRRO Fair ValueKRRO Upside KURA Fair ValueKURA Upside
Bayesian DCF Intrinsic $3.85 -71.3% $3.14 -69.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $9.46 -29.4% $1.03 -89.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KRRO vs KURA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KRRO vs KURA — Which Stock Is More Undervalued?

KURA scores higher with a 5.6/10 quality rating vs KRRO's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Korro Bio, Inc. (KRRO) and Kura Oncology, Inc. (KURA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KRRO currently trades at $13.41 with a QOC of 5.1/10, while KURA trades at $10.20 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).